title: [Effect of lacosamide on the quality of life of patients with epilepsy].
abstract: BACKGROUND
  Epilepsy causes psychiatric disorders in 20-40% of patients impacting negatively on their quality of life. Lacosamide is a new antiepileptic as adjunctive therapy in partial seizures with or without generalization.
  
  
  OBJECTIVE
  We conducted a study to assess the impact of lacosamide as to the quality of life of epileptic patients. We used the HAD scale for anxiety and depression and QOLIE-10 scale for quality of life. We evaluated the efficacy and tolerability.
  
  
  METHODS
  We collected prospectively poorly controlled epileptic patients are and added lacosamide treatment. Baseline visit, at 3 and 6 months were performed. The questionnaires are completed and the epilepsy information has been collected.
  
  
  RESULTS
  31 patients, age 45.5 ± 17.2 years, 64.5% males are included. Number of previous monthly crisis 1.6 ± 1.8. HAD anxiety scale shows a significant improvement at 3 and 6 months. HAD scale for depression reflects a significant improvement in quality parameters. QOLIE-10 shows significant improvement for the group with low quality of life after 3 and 6 months. After 6 months 61.3% of patients have a seizure reduction equal or more than 50% and 54.8% are seizure free. Dizziness is the most common side effect (22.8%). 74.2% continued treatment.
  
  
  CONCLUSIONS
  Lacosamide may improve anxiety, depression and quality of life of epileptic patients regardless of seizure control. Response to treatment, adherence and side effects are similar to previous studies.
authors: Hospital IMED-Levante, Benidorm, Espana.
authors: Alexandre
authors: A
authors: García-Escrivá
authors: Nicolás
authors: N
authors: López-Hernández
authors: Vanessa
authors: V
authors: Llorca
authors: Arantxa
authors: A
authors: Alfaro
authors: Montserrat
authors: M
authors: Asensio-Asensio
authors: César
authors: C
authors: García
authors: Miriam
authors: M
authors: Lezcano-Rodas
authors: Vicente
authors: V
authors: Medrano
authors: Susana
authors: S
authors: Palao
mesh_terms: D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000209:etiology / Q000517:prevention & control*; D003863:Depression / Q000209:etiology / Q000517:prevention & control*; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D000078334:Lacosamide; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index; D026941:Sodium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000081:Acetamides; D000927:Anticonvulsants; D026941:Sodium Channel Blockers; D000078334:Lacosamide